dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Oleas, Diana |
dc.contributor.author | Bolufer Cardona, Monica |
dc.contributor.author | Agraz Pamplona, Irene |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Gabaldon Dominguez, Alejandra |
dc.contributor.author | Bury, Roxana |
dc.contributor.author | Espinel Garuz, María Eugenia |
dc.contributor.author | Serón Micas, Daniel |
dc.contributor.author | García Carro, Clara |
dc.contributor.author | Soler Romeo, Maria Jose |
dc.contributor.author | Muñoz Couselo, Eva |
dc.date.accessioned | 2022-03-22T14:27:06Z |
dc.date.available | 2022-03-22T14:27:06Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Oleas D, Bolufer M, Agraz I, Felip E, Muñoz E, Gabaldón A, et al. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J. 2021 May;14(5):1364–70. |
dc.identifier.issn | 2048-8513 |
dc.identifier.uri | https://hdl.handle.net/11351/7240 |
dc.description | Nefritis intersticial aguda; Inhibidors de punts de control; Biòpsia de ronyó |
dc.description.sponsorship | The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, ISCIII (PI17/00257) and Redinren (RD16/0009/0030). M.B. performed this work as the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. |
dc.language.iso | eng |
dc.publisher | Oxford University Press |
dc.relation.ispartofseries | Clinical Kidney Journal;14(5) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Ronyons - Malalties - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris |
dc.subject.mesh | Nephritis, Interstitial |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /adverse effects |
dc.title | Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/ckj/sfaa008 |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /efectos adversos |
dc.subject.decs | nefritis intersticial |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1093/ckj/sfaa008 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Oleas D, Bolufer M, Agraz I, Bury R, Espinel E, Serón D, García-Carro C, Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Felip E, Muñoz E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gabaldón A] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34221369 |
dc.identifier.wos | 000651847200009 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0009%2F0030 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |